Antenatal TORCH serology: time to start choosing wisely?

Naomi Atkinson1, Lisa Hui 1,2
1. Northern Health, Epping, Victoria, Australia
2. Dept Obstetrics and Gynaecology, University of Melbourne, Heidelberg, Victoria, Australia
Contact: naomi.m.atkinson@gmail.com

Background

- Perinatal TORCH infections (toxoplasmosis, rubella, cytomegalovirus (CMV), herpes simplex (HSV), other) may cause congenital abnormalities and intrauterine growth restriction (IUGR).
- Management of positive or indeterminate serology can be complex, requiring further investigations and specialist consultation.
- TORCH serology is commonly performed for routine investigation of IUGR. Recent studies suggest this is often unnecessary in low risk populations1,2,3,4 and that targeted serology should be considered on a case by case basis.2,5
- We aimed to evaluate the clinical utility and laboratory costs of antenatal TORCH serological screening in an Australian metropolitan non-tertiary hospital with > 3000 births p.a.

Methods

- Retrospective study evaluating antenatal TORCH serology at Northern Health, Melbourne, Australia over a four-year period.
- Laboratory TORCH results and associated clinical records from Jan 2014 – Dec 2017 were analysed.
- TORCH serology performed for stillbirths were excluded.
- A routine “TORCH” serology panel included toxoplasma IgG + IgM, rubella IgG + IgM, CMV IgG + IgM, HSV1 IgG and HSV2 IgG. Syphilis and parvovirus were included at clinician request only.
- The laboratory cost for one TORCH panel was $184.
- Positive/borderline IgM results for CMV, toxoplasma and rubella, and positive HSV IgG results were considered TORCH “screen positive”.
- Perinatal management and outcomes of screen positive cases were manually retrieved from medical records.
- After clinical assessment, screen positive cases were classified as “likely”, “possible” or “unlikely” maternal primary infections.

Results

- 293 TORCH tests were ordered over the 4 year period, most commonly for IUGR (Table 1).
- More than half (n=156; 53.2%) were performed after 32 weeks gestation.
- Discussion re: clinical symptoms/ exposure prior to testing documented in only 9 cases (3%).
- Maternal fetal medicine were involved in decision to test in 9 cases (3%).
- Rubella: 247 women (84%) had prior antenatal documentation of rubella immunity. No positive rubella IgM results were identified.
- HSV1 serology IgG was positive in 167 (57%) women, but these results had no observable impact on management.
- Positive/borderline IgM results for CMV (n=16) and/or toxoplasmosis (n=4) infection were reported in 19 (6.5%) of total TORCH panels.

Table 1. Indications for TORCH testing

<table>
<thead>
<tr>
<th>Indication</th>
<th>Number of cases (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IUGR</td>
<td>241 (82.3%)</td>
</tr>
<tr>
<td>Abnormal ultrasound</td>
<td>43 (14.7%)</td>
</tr>
<tr>
<td>Polyhydramnios</td>
<td>11</td>
</tr>
<tr>
<td>Echogenic bowel</td>
<td>9</td>
</tr>
<tr>
<td>Oligohydranmios</td>
<td>7</td>
</tr>
<tr>
<td>Fetal hydrads</td>
<td>4</td>
</tr>
<tr>
<td>Ventriculomegaly</td>
<td>2</td>
</tr>
<tr>
<td>Other</td>
<td>10</td>
</tr>
<tr>
<td>Clinical suspicion of exposure/illness</td>
<td>6 (2.0%)</td>
</tr>
<tr>
<td>Unclear</td>
<td>3 (1.0%)</td>
</tr>
</tbody>
</table>

Conclusions

- Antenatal TORCH serology was of zero diagnostic yield for congenital infection during the study period and cost > $53,000 in direct lab costs.
- Inconsistency in the interpretation and management of TORCH results highlighted the absence of a well-defined clinical pathway.
- Selective testing for specific infections based on clinical and ultrasound features should replace reflex TORCH serology at our institution.

References


CMV and toxoplasmosis “screen positives” (Figure 1)

- IgG avidity was performed in 12 of 19 cases; all had high avidity (ie infection > 3 months prior to testing).
- 12 women underwent additional assessment, including repeat serology, viral PCR, specialist ultrasound, and/or subspecialist referral.
- There were two cases of “possible” maternal primary CMV, and one of “possible” maternal toxoplasmosis.
- No woman underwent amniocentesis for diagnosis of fetal infection.
- 6 of 19 infants had neonatal TORCH serology; all were considered negative for congenital infection.
- $53,912 in lab costs was expended to identify 0 cases of congenital infection (0%, 95%CI 0.0-1.2%).

Figure 1. Clinical interpretation of serology and neonatal follow up*

- Positive/borderline IgM (CMV IgG, toxoplasmosis IgG)
- 3/11 neonates tested
- 1/11 neonates tested
- 2 subsequently classified false positive (likely no infection) by NPM
- 2/11 neonates tested
- 1/2 neonates tested
- 0/3 neonates tested
- 0/3 neonates tested
- 0/3 neonates tested
- 0/1 neonates tested
- 1 patient unable to be contacted

*All six neonates tested were negative for congenital infection